Your browser doesn't support javascript.
loading
Favorable Outcome of an Exclusively Posttransplant Prophylactic Strategy After Heart Transplantation in Recipients With High Immunological Risk.
Coutance, Guillaume; d'Orio, Virginie; Belin, Lisa; Bréchot, Nicolas; Saheb, Samir; Lebreton, Guillaume; Bouglé, Adrien; Rouvier, Philippe; Gautreau, Chantal; Ouldammar, Salima; Chamillard, Xavier; Huot, Mélanie; Amour, Julien; Combes, Alain; Leprince, Pascal; Varnous, Shaida.
Afiliação
  • Coutance G; Department of Cardiac and Thoracic Surgery, Cardiology Institute, Pitié Salpêtrière Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP). Sorbonne University Medical School, Paris, France.
  • d'Orio V; Department of Cardiac and Thoracic Surgery, Cardiology Institute, Pitié Salpêtrière Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP). Sorbonne University Medical School, Paris, France.
  • Belin L; Department of Cardiology, University Hospital, Liège, Belgium.
  • Bréchot N; Department of Biotatistics, Public Health and Health Information, Pitié Salpêtrière Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP). Sorbonne University Medical School, Paris, France.
  • Saheb S; Department of Medical Intensive Care Unit, Cardiology Institute, Pitié Salpêtrière Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP). Sorbonne University Medical School, Paris, France.
  • Lebreton G; INSERM, UMRS_1166-ICAN, Institute of Cardiometabolism and Nutrition, Paris, France.
  • Bouglé A; Department of Hemo-Biotherapies, Pitié Salpêtrière Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP). Sorbonne University Medical School, Paris, France.
  • Rouvier P; Department of Cardiac and Thoracic Surgery, Cardiology Institute, Pitié Salpêtrière Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP). Sorbonne University Medical School, Paris, France.
  • Gautreau C; Sorbonne Université, UMR INSERM 1166, IHU ICAN, Assistance Publique-Hôpitaux de Paris (AP-HP), Department of Anesthesiology and Critical Care Medicine, Cardiology Institute, Pitié-Salpêtrière Hospital, Paris.
  • Ouldammar S; Department of Pathology, Pitié Salpêtrière Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP). Sorbonne University Medical School, Paris, France.
  • Chamillard X; Laboratory of Immunology and Histocompatibility, AP-HP, Saint Louis Hospital, Paris, France.
  • Huot M; Department of Cardiac and Thoracic Surgery, Cardiology Institute, Pitié Salpêtrière Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP). Sorbonne University Medical School, Paris, France.
  • Amour J; Etablissement Français du Sang, Pitié Salpêtrière Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP). Sorbonne University Medical School, Paris, France.
  • Combes A; Department of Pharmacy, Pitié Salpêtrière Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP). Sorbonne University Medical School, Paris, France.
  • Leprince P; Sorbonne Université, UMR INSERM 1166, IHU ICAN, Assistance Publique-Hôpitaux de Paris (AP-HP), Department of Anesthesiology and Critical Care Medicine, Cardiology Institute, Pitié-Salpêtrière Hospital, Paris.
  • Varnous S; Department of Medical Intensive Care Unit, Cardiology Institute, Pitié Salpêtrière Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP). Sorbonne University Medical School, Paris, France.
Transplantation ; 103(7): 1439-1449, 2019 07.
Article em En | MEDLINE | ID: mdl-30376551
BACKGROUND: Management of the increasing number of sensitized heart transplant candidates has become a recurrent issue. Rather than using pretransplant desensitization therapies, we used a posttransplant prophylactic strategy. Our aim was to describe outcomes in transplant recipients with preformed donor-specific anti-HLA antibodies (pfDSA) managed with this strategy. METHODS: A posttransplant protocol was applied to patients transplanted with pfDSA, consisting of perioperative management of DSA (polyvalent immunoglobulins +/- perioperative plasmapheresis sessions, according to DSA level, as well as induction therapy) and systematic treatment of subsequent antibody-mediated rejection (AMR), even when subclinical. We performed a retrospective analysis of this prospective protocol. The study included all consecutive first recipients of a noncombined heart transplant performed between 2009 and 2015 at our center. The primary endpoint was all-cause mortality. Secondary endpoints included primary graft dysfunction, early posttransplant bleeding, rejection, and cardiac allograft vasculopathy-free survival. RESULTS: A total of 523 patients were studied, including 88 (17%) and 194 (37%) transplanted with DSA mean fluorescence intensity (MFI) of 500 to 1000 and greater than 1000, respectively. The median follow-up period was 4.06 years. Survival was not significantly different between groups. Rejection-free survival was worse in patients with pfDSA MFI >1000, evidenced by a fourfold increase in the risk of antibody-mediated rejection. The incidence of primary graft dysfunction and cardiac allograft vasculopathy-free survival did not significantly differ between groups. Perioperative plasmapheresis increased the risk for transfusion of packed red blood cells. CONCLUSIONS: This exclusively posttransplant prophylactic strategy achieved favorable outcomes in heart transplant recipients with pfDSA.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Dessensibilização Imunológica / Transplante de Coração / Plasmaferese / Imunoglobulinas Intravenosas / Rejeição de Enxerto / Sobrevivência de Enxerto / Histocompatibilidade / Antígenos HLA / Imunossupressores / Isoanticorpos Tipo de estudo: Etiology_studies / Guideline / Observational_studies / Risk_factors_studies Limite: Adult / Female / Humans / Male / Middle aged Idioma: En Revista: Transplantation Ano de publicação: 2019 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Dessensibilização Imunológica / Transplante de Coração / Plasmaferese / Imunoglobulinas Intravenosas / Rejeição de Enxerto / Sobrevivência de Enxerto / Histocompatibilidade / Antígenos HLA / Imunossupressores / Isoanticorpos Tipo de estudo: Etiology_studies / Guideline / Observational_studies / Risk_factors_studies Limite: Adult / Female / Humans / Male / Middle aged Idioma: En Revista: Transplantation Ano de publicação: 2019 Tipo de documento: Article